Hikma launches generic version on Edecrin in the US market

Product adds to the company's non-injectables portfolio in the US.

West-Ward’s Ethacrynic Acid Tablets are indicated for the treatment of edema when an agent with greater diuretic potential than those commonly employed is required. Specifically, West-Ward’s Ethacrynic Acid Tablets are indicated for the following uses: (1) treatment of the edema associated with congestive heart failure, cirrhosis of the liver and renal disease, including the nephrotic syndrome; (2) short-term management of ascites due to malignancy, idiopathic edema, and lymphedema; and (3) short-term management of hospitalized pediatric patients, other than infants, with congenital heart disease or the nephrotic syndrome.

According to IMS Health, US sales of Ethacrynic Acid Tablets USP in 25mg strength were approximately $55 million for the 12 months ending March 2017.

Mike Raya, CEO of West-Ward Pharmaceuticals said: “We are pleased to be adding this product to our non-injectables portfolio in the US. We have a large portfolio and a rich pipeline of differentiated products that we expect will deliver sustainable future growth.”